Tweet
International Business Times
<img alt="" height="1" width="1" />
Bayer Claims ACS Benefit for Xarelto
MedPage Today
Rivaroxaban (Xarelto) plus standard therapy reduced death, myocardial infarction, and stroke in a study of acute coronary syndrome, according to Bayer, which announced the topline results. ...
Bayer's Xarelto could gain edge from new ACS trialFiercePharma
ATLAS-2: Success for rivaroxaban in ACS?TheHeart.Org
J&J and Bayer's Xarelto wins where Pfizer drug lostFierceBiotech
International Business Times -Bloomberg -Wall Street Journal (blog)
all 26 news articles »
More...